Publication: Phospholipid vesicle-bound lysozyme to enhance permeability in human intestinal cells
Issued Date
2013-07-01
Resource Type
ISSN
10979867
10837450
10837450
Other identifier(s)
2-s2.0-84877851153
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmaceutical Development and Technology. Vol.18, No.4 (2013), 821-827
Suggested Citation
Wasu Witoonsaridsilp, Busaba Panyarachun, Montree Jaturanpinyo, Narong Sarisuta Phospholipid vesicle-bound lysozyme to enhance permeability in human intestinal cells. Pharmaceutical Development and Technology. Vol.18, No.4 (2013), 821-827. doi:10.3109/10837450.2012.700930 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/32734
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Phospholipid vesicle-bound lysozyme to enhance permeability in human intestinal cells
Other Contributor(s)
Abstract
Background: Oral peptide and protein drug delivery still remain the area of challenges for pharmaceutical scientists due to their low stability and permeability in gastrointestinal (GI) tract. In this study phospholipid vesicle-bound lysozyme were prepared and assessed for their physicochemical properties, secondary structure, and permeation across Caco-2 cells. Results: Lysozyme was found to be substantially bound onto negatively charged vesicles via electrostatic interaction as evidenced by zeta potential measurements regardless of cholesterol content. In contrast, the size of phospholipid vesicle-bound lysozyme became larger with the increasing cholesterol content. The secondary structure of vesicle-bound lysozyme examined by FTIR was unchanged compared to that in buffer solution. The apparent permeability of vesicle-bound lysozyme across Caco-2 cells monolayer was significantly enhanced with a size dependent manner compared to that of solution. Conclusion: The permeation across Caco-2 cell monolayers of phospholipid vesicle-bound lysozyme was demonstrated to be significantly enhanced with a size-dependent manner. © 2013 Informa Healthcare USA, Inc.